Reduced risk of influenza and pneumonia (HR 0.94; 95% CI 0.92-0.96) and pulmonary fibrosis (HR 0.92; 95% CI 0.87-0.98) were also noted in GLP-1 RA users. This evidence concerns the gene GLP1R and influenza.